Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Walt Disney Co (DIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Walt Disney Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Walt Disney Co trades at $97.37 (market cap $169.28B). The key difference: Walt Disney Co is far larger — about 37.7× ACADIA Pharmaceuticals Inc.'s market cap, and Walt Disney Co pays a 1.54% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DIS | |
|---|---|---|
Market Cap | $4.49B | $169.28B |
Sector | Health | Media |
52-Week High | $28.06 | $122.94 |
52-Week Low | $20.06 | $92.40 |
Enterprise Value | $3.69B | $210.95B |
Volume | — | 7,546,013 |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Disney (DIS) trades at $97.41, down 2.06% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $1.88. Revenue growth has accelerated from $82.7B in 2022 to $94.4B in 2025, while net income surged to $12.4B. Analyst consensus remains strongly bullish with a $131.89 price target, representing 35% upside potential from current levels.
Disney presents a compelling investment case with improving profitability and strong cash flow generation, though regulatory challenges and recent box office disappointments pose near-term risks. The stock's current valuation at 15.59x P/E appears attractive relative to growth prospects, while technical indicators suggest potential support near $94-96 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →
